Equities analysts expect that Zynex Inc. (NYSE:ZYXI) will post $17.62 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Zynex’s earnings. The highest sales estimate is $17.80 million and the lowest is $17.50 million. Zynex reported sales of $10.30 million during the same quarter last year, which indicates a positive year-over-year growth rate of 71.1%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Zynex will report full-year sales of $79.92 million for the current financial year, with estimates ranging from $77.73 million to $81.52 million. For the next fiscal year, analysts expect that the firm will report sales of $126.65 million, with estimates ranging from $105.00 million to $138.30 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Zynex.
Zynex (NYSE:ZYXI) last issued its earnings results on Tuesday, April 28th. The company reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.02. The firm had revenue of $15.23 million for the quarter, compared to the consensus estimate of $15.07 million.
Separately, HC Wainwright downgraded Zynex from a “buy” rating to a “neutral” rating in a report on Tuesday, May 19th.
NYSE ZYXI traded up $1.46 on Friday, reaching $24.64. 433,573 shares of the stock traded hands, compared to its average volume of 684,271. The company has a fifty day moving average price of $21.17 and a 200-day moving average price of $13.66. Zynex has a 12 month low of $7.12 and a 12 month high of $27.00.
Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device.
Further Reading: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.